There were no further statistically significant increase of the risk in terms of aHR in children with JIA treated with either methotrexate whose aHR, 2.72 (95% CI, 0.85 – 8.73; P = 0.0932) or TNF-alpha inhibitors whose aHR, 6.05 (95% CI, 0.82 – 44.61; P = 0.0772) (Table 4). This evidence concerns the gene TNF and juvenile idiopathic arthritis.